COVID-19 drug vaccine clinical trials by type worldwide June 2022| Statista

As of June 3, 2022, there were over 2,700 trials testing treatments for the coronavirus disease (COVID-19) worldwide. In addition, there were 1,752 trials of COVID-19 vaccines in some phase of clinical development.

Number of coronavirus (COVID-19) clinical trials for drugs and vaccines worldwide as of June 3, 2022, by type*

Characteristic	Number of trials
Treatment	2,704
COVID-19 vaccines	1,752
Moderate COVID-19	1,345
COVID-19 complication support	1,287
Severe COVID-19	1,256
COVID-19 pneumonia	1,197
Mild COVID-19	1,152
Healthy subjects	1,149
Critical COVID-19	461
Exposure prophylaxis (PEP/PrEP)	418
Asymptomatic COVID-19	254
Post-COVID syndrome	115
Unspecified	186

02004006008001,0001,2001,4001,6001,8002,0002,2002,4002,6002,8003,000

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

June 2022

More information

Region

Worldwide

Survey time period

as of June 3, 2022

Supplementary notes

* Definition of listed types:
Treatment: Trials intending to treat (rather than prevent) novel coronavirus (2019-nCoV, COVID-19).
COVID-19 Complication Support: Trials aiming to prevent or treat complications of COVID-19 infection, such as ARDS, Cytokine storm, AKI, Sepsis, etc.
Novel coronavirus (2019-nCoV, COVID-19) pneumonia: Trials that aim to treat or prevent pneumonia due specifically to novel coronavirus (2019-nCoV).
Severe COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms (requiring supplemental oxygen) at screening.
Moderate COVID-19: Trials enrolling subjects with confirmed COVID-19 that have moderate symptoms (respiratory symptoms but supplemental oxygen not needed) at screening.
Mild COVID-19: Trials enrolling subjects with confirmed COVID-19 that have mild upper respiratory symptoms at trial screening.
Novel coronavirus (2019-nCoV, COVID-19) vaccines: Trials with vaccines intended to prevent/treat novel coronavirus (2019-nCoV, COVID-19).
Critical COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms at screening and are in the ICU for critical support. These subjects are likely already on ventilatory support.
Exposure prophylaxis (PEP/PrEP): Trials aiming to prevent COVID-19 infection in subjects at high risk of exposure (ex. Healthcare workers). Includes trials where confirmed exposure has taken place (post-exposure prophylaxis: PEP) as well as trials treating subjects prior to first exposure (pre-exposure prophylaxis: PrEP).
Healthy subjects: Trials enrolling only healthy subjects.
Asymptomatic COVID-19: Trials enrolling subjects with confirmed COVID-19 that are asymptomatic at screening.
Post-COVID Syndrome: Trials aiming to treat Post-COVID Syndrome, including treatment of persistent lung, cardiac or kidney injury after COVID-19 infection.
Unspecified: Trials enrolling patients (not healthy volunteers) but not otherwise specified.

Citation formats